Pharmaceutical Testing and Analytical Services Market

SGS bought CMIC, INC., a 27,000-square-foot Good Laboratory Practice (GLP) bioanalytical laboratory in Chicago, and announced the deal on 3 June 2026, its second North American bioanalysis purchase within a month. Pharmaceutical testing and analytical services are the outsourced laboratory tests that prove a medicine’s identity, strength, purity, stability and safety; the market covers bioanalysis, stability, method validation, release, microbiology and extractables work bought by drug sponsors. Douglas Insights sizes the pharmaceutical testing and analytical services market at USD 9.32 billion in 2025, which is 38.62 million billable analytical results multiplied by an average USD 241.3 per result. Our base case reaches USD 19.1 billion in 2035, a revenue CAGR of 7.46% made of 5.14% volume growth and 2.21% price growth. Related studies sit on the pharmaceutical testing and quality services hub, and every step of the build can be checked against the Douglas Insights research methodology.

Which companies win the most pharmaceutical batch-release and bioanalytical testing work?

Eurofins wins the largest slice, about 15.8% of pharmaceutical testing and analytical services revenue in 2025 by Douglas Insights estimate, followed by SGS at 4.7% and Charles River at 4.2%. The top three hold 24.7%, so thousands of regional GLP and current Good Manufacturing Practice (cGMP) laboratories share the remaining 75.3%.

Eurofins builds its lead on scale. The group reported BioPharma segment revenues of EUR 2.06 billion in its full-year 2025 results, 28% of group revenues of EUR 7.30 billion, with 1.4% organic growth and a network of more than 950 laboratories in 59 countries. That segment also holds agroscience, genomics and forensic work, so Douglas Insights attributes 63% of it, about USD 1.47 billion at 1.13 USD per EUR, to drug product testing and bioanalysis. Eurofins named demand from GLP-1 therapy projects as an offset to muted early-stage biotech spending. Charles River Laboratories reported 2025 revenue of USD 4.02 billion, with Manufacturing Solutions at USD 766.4 million and Discovery and Safety Assessment at USD 2.40 billion; only the release and microbial testing slice counts here.

SGS is the buyer to watch. Scale matters here. Its 4 May 2026 purchase of Keystone Bioanalytical, a Philadelphia liquid chromatography with tandem mass spectrometry (LC-MS/MS) laboratory founded in 2001 with a 10,000-square-foot GLP facility, came before the CMIC deal, and both serve the SGS Strategy 27 goal of doubling North American sales between 2023 and 2027. SGS runs more than 20 pharmaceutical laboratories in 11 countries, 10 of them GLP-compliant. WuXi AppTec reported WuXi Testing revenue of RMB 4.04 billion for 2025, up 4.7%, anchored on drug safety evaluation in Asia Pacific. Intertek sells method development, stability, extractables and leachables and batch release testing from a GLP and cGMP laboratory network. Element Materials Technology entered pharmaceutical analytics through acquisitions such as Avomeen, an Ann Arbor laboratory with an 80-person scientific team.

The table shows why concentration stays low: below the top three, no pharmaceutical testing provider in our model clears 2.5% of revenue.

What does the pharmaceutical testing and analytical services market include, from release assays to extractables?

The pharmaceutical testing and analytical services market includes six outsourced service lines worth USD 9.32 billion in 2025, from LC-MS/MS bioanalysis of clinical plasma samples to sterility tests on finished vials. In-house quality control (QC) laboratories run by drug sponsors, instrument sales and clinical diagnostics sit outside the scope.

The scope counts work by service, by molecule type and by client. Service lines are Bioanalytical testing, Stability testing, Method development and validation, Raw material and batch release testing, Microbiology and sterility testing, and Extractables and leachables testing. Molecule types are Small molecules, Biologics, and Cell and gene therapies. Client groups are Large pharmaceutical companies, Biotechnology firms, Generic drugmakers, and Contract development and manufacturing organisations. Endotoxin work is counted in microbiology. Single-use bags and filters are covered in our Biopharmaceutical Single-Use Bioprocessing Market study.

Which service segment makes the money: stability, bioanalysis or release testing?

Bioanalytical testing makes the most money: USD 2.29 billion, or 24.6% of pharmaceutical testing and analytical services revenue in 2025. Every clinical pharmacokinetic study ships thousands of plasma samples to validated LC-MS/MS and ligand-binding platforms. Stability testing follows at 21.3%. Release testing trails. Nothing else comes close.

Bioanalytical testing, at USD 2.29 billion, is also the fastest-growing line at 8.96% a year, because biologics and GLP-1 programmes need large-molecule assays, anti-drug antibody panels and dense sampling schedules. Stability testing earns USD 1.98 billion since every commercial batch of a pharmaceutical product needs long-term and accelerated pulls at fixed time points for years. Method development and validation brings in USD 1.66 billion, driven by new filings and by sponsors rewriting procedures to the revised validation guideline. Raw material and batch release testing totals USD 1.57 billion; its 5.94% rate is the slowest because mature generics release volumes grow with prescriptions, not with pipelines. Microbiology and sterility testing reaches USD 1.22 billion on the back of sterile injectable output and stricter contamination control. Extractables and leachables testing is the smallest line at USD 587.1 million but grows 8.27% a year as prefilled syringes, bags and single-use systems spread.

Why are drug sponsors sending more stability and nitrosamine testing to contract laboratories?

Douglas Insights expects billable pharmaceutical testing results to rise 5.14% a year, from 38.62 million in 2025 to 63.75 million in 2035. Sponsors outsource because compliance deadlines, biologics pipelines and lean in-house QC teams all push test volumes up across all six service lines.

The outsourcing shift adds 1.83 points a year. Douglas Insights models large drugmakers moving overflow stability, method transfer and release testing to contract networks rather than adding fixed laboratory headcount. SGS said its Keystone Bioanalytical and CMIC deals answer growing demand for GLP bioanalysis, and the CMIC purchase added 27,000 square feet of capacity in Chicago alone; consolidators buy capacity when they see sponsors handing over work for good. Eurofins runs more than 950 laboratories, and its latest annual results credit GLP-1 therapy projects with offsetting softer biotech demand.

Biologics and peptide pipelines add 1.96 points a year. A monoclonal antibody or GLP-1 peptide programme needs ligand-binding assays, immunogenicity panels, glycan mapping and charge-variant profiling, so a single clinical study can generate several times the analytical results of a comparable small-molecule study. Douglas Insights counts biologics at 36.7% of pharmaceutical testing revenue in 2025, worth USD 3.42 billion, against 57.6% for small molecules.

Compliance rules add 1.35 points a year. The US Food and Drug Administration (FDA) guidance on nitrosamine impurities, first issued on 24 February 2021 and revised in September 2024, set 1 August 2025 as the recommended date for controlling nitrosamine drug substance-related impurities (NDSRIs). Every affected product needs a risk assessment and often confirmatory high-resolution mass spectrometry, work few generic drugmakers can run internally. Sterile manufacturers face the same pressure from the revised European Union Good Manufacturing Practice (GMP) Annex 1 on contamination control, which drives environmental monitoring and sterility test volume.

Douglas Insights tracks 38.62 million billable results across six service lines, and its compliance calendar ties 1.45 million of the added yearly volume to six dated rules. Douglas Insights counts 3.8% of the 2025 base as rule-driven before any new filing is considered. Outsourcing wins when a sponsor faces a deadline. It loses when a sponsor has idle instruments.

Together the three drivers add 5.14 points, which equals the volume leg of the pharmaceutical testing model. Price adds 2.21% a year more, mostly from the mix shift toward high-resolution mass spectrometry and biologics characterisation rather than list-price increases.

Which hurdles cut outsourced pharmaceutical testing volumes, from analyst shortages to biotech funding?

Three hurdles remove 0.82 points a year from pharmaceutical testing volume growth. The volume leg therefore settles at 5.14% instead of 5.96%, held down by scarce trained analysts, uneven biotech funding and selective insourcing by large drugmakers with spare QC capacity in their own release laboratories.

Analyst scarcity removes 0.37 points. Training takes time. A GMP chemist needs months of training before signing release data, and turnaround on stability and release work stretches when senior staff leave. Laboratories respond with wage increases that feed the 2.21% price leg but cap how many results each site can deliver.

Biotech funding removes 0.31 points. Cycles matter. Eurofins reported only 1.4% organic BioPharma growth in its latest full year and cited muted early-stage spending by biotech clients. Charles River reported a 0.9% revenue decline over the same year, to USD 4.02 billion. Biotechnology firms buy 27.8% of outsourced pharmaceutical testing in our model, so a funding pause hits bioanalysis and method development first.

Insourcing removes 0.14 points. It is the smallest hurdle. Some large pharmaceutical companies with new QC buildings pull routine release testing back in-house, keeping contract laboratories for overflow, nitrosamine confirmation and specialist extractables work.

Where is pharmaceutical QC testing capacity growing fastest, North America or Asia Pacific?

North America leads pharmaceutical testing and analytical services with USD 3.89 billion, or 41.7% of 2025 revenue. Asia Pacific grows fastest at 10.46% a year, from USD 2.01 billion to USD 5.44 billion by 2035, as contract laboratories in India and China take more global stability and release work.

North America grows 6.62% a year to USD 7.38 billion by 2035, carried by biologics bioanalysis and the consolidation SGS is pursuing under Strategy 27. Europe holds USD 2.74 billion and grows 6.05% to USD 4.93 billion, its pace set by Annex 1 sterile testing and steady generics release work. Asia Pacific overtakes Europe by 2035 because Indian generic drugmakers face the same nitrosamine controls as US sponsors and WuXi Testing returned to 4.7% growth in 2025. Latin America brings in USD 400.7 million and grows 7.31% to USD 811.4 million, mainly Brazilian and Mexican generics release testing. Middle East and Africa is the wildcard: USD 279.6 million in 2025 growing 7.57% to USD 580.0 million, with outcomes tied to whether new regional fill-finish capacity creates local demand for sterility and stability laboratories.

How much do sponsors pay per HPLC assay, stability pull or bioanalytical sample?

Sponsors pay an average USD 241.3 per billable pharmaceutical testing result in 2025, rising to about USD 300.3 by 2035. Realised prices span from under USD 100 for a routine bioanalytical sample in a large batch to several thousand dollars for a nitrosamine confirmation.

Douglas Insights puts realised price bands, drawn from contract quotes and laboratory rate cards in our model, as follows. A high-performance liquid chromatography (HPLC) assay or related-substances test runs USD 180 to USD 420 per sample. A full stability pull, with assay, impurities, dissolution and water content at one time point, costs USD 900 to USD 2,600. A validated LC-MS/MS bioanalytical sample in a clinical study costs USD 95 to USD 260. A nitrosamine confirmatory test by high-resolution mass spectrometry costs USD 1,400 to USD 3,800 per sample. A compendial sterility test runs USD 350 to USD 900, and a method validation package costs USD 18,000 to USD 65,000.

The 2.21% annual price leg reflects mix more than inflation. Mix wins. Every point of revenue that moves from routine HPLC release work to biologics characterisation lifts the average result price, which is why pharmaceutical testing revenue outgrows result volume across the decade.

Are biologics and cell therapy batches raising analytical testing intensity per lot?

Yes. Biologics account for 36.7% of pharmaceutical testing revenue, USD 3.42 billion in 2025. Cell and gene therapies add another 5.7%, or USD 531.2 million, and their release panels need far more assays per lot than a tablet batch, pushing analytical intensity up.

Small molecules still carry 57.6% of revenue, USD 5.37 billion, because generic volumes are huge and each product still needs release and stability work. A monoclonal antibody lot, by contrast, needs potency bioassays, glycan analysis, aggregate and charge-variant testing, host-cell protein assays and sterility, and a cell therapy lot adds identity, vector copy number and replication-competent virus tests under tight release clocks. Sterile filling links these lots to our Sterile Injectable Contract Manufacturing Market study, since each new fill line creates a stream of release and environmental samples.

Do generic drugmakers or biotech firms buy more outsourced analytical testing hours?

Large pharmaceutical companies buy the most outsourced analytical testing: 39.2% of pharmaceutical testing revenue, or USD 3.65 billion in 2025. Biotechnology firms follow at 27.8% and USD 2.59 billion, ahead of generic drugmakers at 19.3% and USD 1.80 billion, whose spending jumps around nitrosamine and release deadlines.

Contract development and manufacturing organisations hold 13.7%, worth USD 1.28 billion, buying specialist tests they do not run themselves. Biotechnology firms outsource almost everything because few own GMP laboratories, which is why their funding cycle swings bioanalysis volumes. Generic drugmakers buy in bursts tied to regulatory events such as the NDSRI deadline, and they purchase high-purity water and reagents covered in our Laboratory Grade Water Market study for the tests they keep in-house.

How do Annex 1, ICH Q2(R2) and FDA nitrosamine rules reshape laboratory workloads?

Three rule sets add about 1.35 points a year to pharmaceutical testing volumes. They are EU GMP Annex 1 on sterile manufacture, ICH Q2(R2) and Q14 on analytical procedures, and the FDA nitrosamine guidance, each forcing new or repeated tests on existing products.

The European Commission published revised Annex 1 on 25 August 2022 and set 25 August 2023 as its operational deadline, with point 8.123 postponed until 25 August 2024. Contamination control strategies under Annex 1 raise environmental monitoring and sterility testing frequency at every sterile site that supplies Europe.

The International Council for Harmonisation (ICH) guidelines Q2(R2) on validation and Q14 on analytical procedure development reached Step 4 in November 2023, according to an FDA training presentation. Sponsors updating legacy dossiers commission revalidation work, which supports the 7.83% growth rate of method development and validation. The FDA nitrosamine guidance, with its 1 August 2025 NDSRI date, sits behind the fastest burst of confirmatory mass spectrometry demand in the pharmaceutical testing market since 2021.

Which 2035 forecast cases matter for GLP bioanalysis and QC release testing?

Three forecast cases bracket pharmaceutical testing and analytical services in 2035: USD 15.4 billion slower, USD 19.1 billion base and USD 23.6 billion faster. Biotech funding and the pace of outsourcing to contract laboratories separate the three cases far more than price does.

The base case pairs 5.14% volume growth with 2.21% price growth for a 7.46% CAGR. The slower case uses 3.62% volume and 1.48% price, reaching USD 15.4 billion if biotech funding stays weak and large drugmakers insource release work. The faster case uses 6.68% volume and 2.86% price, reaching USD 23.6 billion if consolidators such as SGS keep buying GLP bioanalysis capacity at the pace set by the May and June 2026 deals and biologics share rises faster. Raising volume growth by 1 point lifts the 2035 value to USD 21.0 billion; cutting it by 1 point lowers it to USD 17.4 billion.

Our 7.46% lands in the upper half of a 5.98% to 8.5% spread of published forecasts, because it counts biologics bioanalysis in full rather than only small-molecule outsourcing.

Douglas Exclusive: the Pharmaceutical Testing Compliance Calendar

The Pharmaceutical Testing Compliance Calendar is a Douglas Insights model built from 13 inputs: 6 regulatory milestones, 4 laboratory acquisitions and 3 annual results releases, each tied to a primary source. It maps when a rule or deal changes testing demand and estimates the extra billable results each event triggers.

The calendar counts 1.45 million added billable results a year from the six regulatory milestones, or 3.8% of the 38.62 million results counted for 2025. The finding: rules, not deals, create net new pharmaceutical testing demand, while acquisitions such as the two SGS purchases move existing bioanalysis work between owners. Licensees receive the calendar with each milestone’s source and the arithmetic behind every estimate.

How does the methodology turn billable HPLC, microbiology and bioanalytical results into a market value?

The methodology multiplies 38.62 million billable pharmaceutical testing results by an average USD 241.3 per result to reach USD 9.32 billion for 2025. Volume then grows at 5.14% and price at 2.21% a year, reaching USD 19.1 billion in 2035 across five regions and six service lines.

The model rests on 5 regions, 6 service lines, 3 molecule types, 4 client groups, 13 dated calendar inputs and 4 published growth rates. Volume comes from billable result counts by service line; price comes from the band midpoints in the pricing section, weighted by mix. Regions sum to USD 9.32 billion in 2025 and USD 19.1 billion in 2035, and segment values sum to USD 9.32 billion in 2025 and to within 0.7% of the 2035 total. The first cross-check compares our base with published 2025 estimates of USD 9.6 billion and USD 9.78 billion for a narrower outsourcing scope; our figure sits 2.9% and 4.7% below them. The second cross-check reads company filings: Eurofins and Charles River together hold 20.0% in our share table, consistent with their disclosed BioPharma and Manufacturing Solutions revenues after non-pharmaceutical work is removed. The third check places our 7.46% CAGR inside the published range of 5.98% to 8.5%.

Sources

1. SGS SGS acquisition of CMIC, INC. (2026)
2. SGS SGS acquisition of Keystone Bioanalytical (2026)
3. Eurofins Scientific Eurofins 2025 full year results (2026)
4. Charles River Laboratories Charles River fourth-quarter and full-year 2025 results (2026)
5. WuXi AppTec WuXi AppTec 2025 results (2026)
6. US Food and Drug Administration Control of Nitrosamine Impurities in Human Drugs (2024)
7. European Commission Revision of EU GMP Annex 1 (2022)
8. US Food and Drug Administration Q2(R2)/Q14 training presentation (2024)